

## 3-[(6-Arylamino)pyridazinylamino]benzoic acids: design, synthesis and in vitro evaluation of anticancer activity

Khaled A. M. Abouzid · Nadia A. Khalil ·  
Eman M. Ahmed · Khaled Omar Mohamed

Published online: 11 January 2013

© The Pharmaceutical Society of Korea and Springer Science+Business Media Dordrecht 2013

**Abstract** A series of novel substituted 3,6-disubstituted pyridazines based on the structure of vatalanib (PTK787) were designed and synthesized. The cytotoxicity of the final compounds was tested in vitro on HT-29 colon cancer cell line. Compounds **2a** and **2b** with 4-chlorophenylamino moiety, exerted the highest cytotoxic activity with IC<sub>50</sub> values equal to 15.3 and 3.9 μM respectively. The most promising compound, **2b**, was found to be about fivefold more active than vatalanib against HT-29 colon cancer cell line.

**Keywords** Pyridazine · Colon cancer · Vatalanib · Cytotoxic

### Introduction

Cancer represents the second leading cause of human mortality after cardiovascular diseases (Eckhardt 2002; Lee et al. 2002). Although chemotherapy is the mainstay of cancer therapy, the use of available chemotherapeutics still suffers from major limitations, such as lack of selectivity for cancer tissues, bringing about unwanted side effects and the acquisition by cancer cells of multiple-drug resistance (Rojo et al. 2008). Therefore, the search for new drugs, which can selectively target the tumor cells is today's goal of cancer therapy. In the recent years, inhibition of the VEGFR-2

(vascular endothelial growth factor receptor) signalling pathway, approved to have an antiangiogenic effect on human cancers (Dvorak 2002). In addition, the small-molecule VEGFR-2 kinase inhibitors, sorafenib (Ahman and Eisen 2004) and pazopanib (Podar et al. 2004) (GW786034) have been approved for the treatment of advanced renal cell carcinoma (Morabito et al. 2006). Vatalanib (PTK-787), a 1,4-disubstituted phthalazine VEGFR inhibitor, is currently in phase III clinical trials for metastatic colorectal cancer (Scott et al. 2007) (Fig. 1).


Introduction of appropriate heterocycles into a lead compound is a common strategy in the drug discovery process. A wide range of heterocyclic ring systems have been studied for the development of novel chemical entities as lead molecules.

Over the past years, pyridazine derivatives have been extensively studied and have shown a wide range of pharmacological activities such as antidepressant (Coelho et al. 2003), antihypertensive (Siddiqui et al. 2010), anticonvulsant (Rubat et al. 1990) cardiotoxic (Sircar et al. 1987), antibacterial (Kandile et al. 2009), hepatoprotective (Kwon and Moon 2005), anti-HIV (Livermone et al. 1993), COX-2 inhibitor (Harris et al. 2004), and anticancer (Ahmad et al. 2010; Abd El-Ghaffar et al. 2011) activities. The encouraging anticancer activity observed by pyridazine derivatives prompted us to investigate new analogues involving modification of the structure of vatalanib. The introduction of new substituents or functional groups at various positions on aromatic or heteroaromatic fragments of a potential drug might lead to changes in its molecular shape that allows optimum binding to the receptor, as well as its physico-chemical properties that affect drug distribution and metabolism (Piatnitski et al. 2005). Our strategy was directed toward designing a variety of ligands with diverse chemical properties hypothesized that the potency of the molecule

K. A. M. Abouzid  
Pharmaceutical Chemistry Department, Faculty of Pharmacy,  
Ain Shams University, Cairo 11566, Egypt

N. A. Khalil · E. M. Ahmed (✉) · K. O. Mohamed  
Pharmaceutical Organic Chemistry Department,  
Faculty of Pharmacy, Cairo University, Cairo, Egypt  
e-mail: dr\_eman2001@hotmail.com

**Fig. 1** Structures of VEGFR kinase inhibitors under clinical investigation and the designed compounds



might be enhanced by adding alternative binding group such as carboxylic acid, amide, or sulphonamide group in the aniline moiety.

The design of our ligands was based on the replacement of the phthalazine scaffold in vatalanib by pyridazine ring, which was connected with the aryl system via a heteroatom, as well as replacement of the chlorine atom in vatalanib by an electron withdrawing carboxylic function with the hope of attaining superior biological activity. Furthermore, a number of novel sulphonamide derivatives have recently been reported to show substantial antitumor activity both in vitro and/or in vivo (Kamal et al. 2011; Rathish et al. 2012). In this direction, we introduced larger moiety at 4 position of aniline such as sulphonamido or heterocyclylsulphonamido, so that the bulky group could be oriented deep in the binding site, and makes predominantly hydrophobic interactions with the protein (Fig. 1).

## Materials and methods

### Chemistry

All chemicals and reagents were obtained from Aldrich (Sigma-Aldrich), and were used without further purification.

Reactions were monitored by TLC, performed on silica gel glass plates containing 60 GF-254, and visualization on TLC was achieved by UV light or iodine indicator. IR spectra were determined on Shimadzu IR 435 spectrophotometer (KBr,  $\text{cm}^{-1}$ ). <sup>1</sup>HNMR spectra were carried out using a Mercury 300-BB 300 MHz using TMS as internal standard. Chemical shifts ( $\delta$ ) are recorded in ppm on  $\delta$  scale, Micro analytical Center, Cairo University, Egypt. <sup>13</sup>CNMR spectra were carried out using a Mercury 300-BB 75 MHz using TMS as internal standard. Chemical shifts ( $\delta$ ) are recorded in ppm on  $\delta$  scale, Micro analytical Center, Cairo University, Egypt. Mass spectra were recorded on Shimadzu Qp-2010 plus spectrometer, Micro analytical Center, Cairo University, Egypt. Elemental analyses were carried out at the Micro analytical Center, Cairo University, Egypt. Melting points were determined with Stuart apparatus and are uncorrected.

The starting material 3,6-dichloropyridazine is commercially available. 6-Chloro-3-substituted-aminopyridazines (Abouzid et al. 2012) **1a–h**, 2-(6-chloropyridazine-3-ylloxy)benzamide (Abouzid et al. 2012) (**3**) and 4-(6-chloropyridazin-3-ylamino) benzenesulphonamide (Mariño et al. 1980) (**5a**) were prepared as reported.

All chemicals were obtained from Aldrich, Fluka, or Merck chemicals.

General procedure for **2a–h**, **4a**, **b** and **6a–f**

A mixture of an equimolar amounts of the appropriate **1a–h**, **3** or **5a–c** and an appropriate amino benzoic acid (0.01 mol each) in isopropanol (30 mL) was heated under reflux for 4–5 h. The solution was concentrated under reduced pressure to half its volume and cooled. The separated solid was filtered, washed with sodium carbonate solution (20 mL), dried and crystallized from isopropanol.

*3-[[6-[(4-Chlorophenyl)amino]pyridazin-3-yl]amino]benzoic acid (2a)*

Yield: 70 %; mp 141–142 °C; IR (cm<sup>-1</sup>): 3421–2553 (N–H and O–H), 1685 (C=O), 1631 (C=N); <sup>1</sup>HNMR (300 MHz, DMSO-*d*<sub>6</sub>) δ ppm: 6.73 (d, 1H, pyridazine), 6.76 (d, 1H, pyridazine), 7.05–5.07 (m, 4H, Ar–H), 7.12 (d, 2H, Ar–H), 7.16 (d, 2H, Ar–H), 8.05 (s, 1H, NH D<sub>2</sub>O exchangeable), 9.83 (s, 1H, NH D<sub>2</sub>O exchangeable); MS (EI) *m/z* (% rel. Int.): 342 (M+2, 0.57), 340 (M<sup>+</sup>, 5.00), 261 (23.18), 204 (6.96), 135 (9.22). Anal. Calcd for C<sub>17</sub>H<sub>13</sub>ClN<sub>4</sub>O<sub>2</sub>: C, 59.92; H, 3.85; N, 16.44; Found C, 59.78; H, 3.98; N, 16.56.

*4-[[6-(4-Chlorophenyl)amino]pyridazin-3-ylamino]benzoic acid (2b)*

Yield: 65 %; mp 129–130 °C; IR (cm<sup>-1</sup>): 3471–2546 (N–H and O–H), 1678 (C=O), 1624 (C=N); <sup>1</sup>HNMR (300 MHz, DMSO-*d*<sub>6</sub>) δ ppm: 6.54 (d, 1H, pyridazine), 6.57 (d, 1H, pyridazine), 6.88 (dd, 2H, Ar–H), 7.22 (dd, 2H, Ar–H), 7.58–7.78 (m, 4H, Ar–H), 8.04 (s, 1H, NH D<sub>2</sub>O exchangeable), 9.88 (s, 1H, NH D<sub>2</sub>O exchangeable); MS (EI) *m/z* (% rel. Int.): 342 (M+2, 0.01), 340 (M<sup>+</sup>, 0.03), 137 (100). Anal. Calcd for C<sub>17</sub>H<sub>13</sub>ClN<sub>4</sub>O<sub>2</sub>: C, 59.92; H, 3.85; N, 16.44; Found C, 59.88; H, 3.65; N, 16.15.

*3-[[6-(2,4-Dichlorophenyl)amino]pyridazin-3-ylamino]benzoic acid (2c)*

Yield: 60 %; mp 209–210 °C; IR (cm<sup>-1</sup>): 3421–2561 (N–H and O–H), 1685 (C=O), 1627 (C=N); <sup>1</sup>HNMR (300 MHz, DMSO-*d*<sub>6</sub>) δ ppm: 7.26 (d, 1H, pyridazine), 7.30 (d, 1H, pyridazine), 7.30–7.69 (m, 5H, Ar–H), 7.95 (d, 1H, Ar–H), 8.03 (s, 1H, NH D<sub>2</sub>O exchangeable), 8.39 (s, 1H, Ar–H), 9.87 (s, 1H, NH D<sub>2</sub>O exchangeable); EIMS (% rel. abundance): 376 (M+2, 0.00), 374 (M<sup>+</sup>, 0.00), 161 (19.84), 137 (100), 120 (39.29), 92 (40.30). Anal. Calcd for C<sub>17</sub>H<sub>12</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>2</sub>: C, 54.42; H, 3.22; N, 14.93; Found C, 54.15; H, 3.35; N, 14.82.

*4-[[6-(2,4-Dichlorophenyl)amino]pyridazin-3-ylamino]benzoic acid (2d)*

Yield: 75 %; mp 239–240 °C; IR (cm<sup>-1</sup>): 3294–2546 (O–H and N–H), 1666 (C=O), 1612 (C=N); <sup>1</sup>HNMR (300 MHz, DMSO-*d*<sub>6</sub>) δ ppm: 6.68 (d, 1H, pyridazine), 6.71 (d, 1H, pyridazine), 7.27–7.34 (m, 3H, Ar–H), 7.62–7.93 (m, 4H, Ar–H), 8.03 (s, 1H, NH D<sub>2</sub>O exchangeable), 9.95 (s, 1H, NH D<sub>2</sub>O exchangeable); <sup>13</sup>CNMR (75 MHz, DMSO) δ ppm: 114.50 (2C, Ar), 117.40 (1C, Ar), 117.50 (1C, Ar), 120.97 (2C, pyridazine), 123.10 (1C, Ar), 129.53 (1C, Ar), 130.49 (2C, Ar), 131.06 (2C, Ar), 144.26 (1C, Ar), 148.12 (1C, Ar), 156.42 (2C, pyridazine), 167.19 (1C, CO); EIMS (% rel. abundance): 378 (M+4, 2.67), 376 (M+2, 1.59), 144 (13.18). Anal. Calcd for C<sub>17</sub>H<sub>12</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>2</sub>: C, 54.42; H, 3.22; N, 14.93; Found C, 54.35; H, 3.10; N, 14.77.

*3-[[6-(2,6-Dichlorophenyl)amino]pyridazin-3-ylamino]benzoic acid (2e)*

Yield: 62 %; mp 197–198 °C; IR (cm<sup>-1</sup>): 3294–2557 (O–H and N–H), 1685 (C=O), 1627 (C=N); <sup>1</sup>HNMR (300 MHz, DMSO-*d*<sub>6</sub>) δ ppm: 7.20 (d, 1H, pyridazine), 7.23 (d, 1H, pyridazine), 7.40–7.97 (m, 6H, ArH), 8.39 (s, 1H, ArH), 8.03 (s, 1H, N–H D<sub>2</sub>O exchangeable), 9.81 (s, 1H, N–H D<sub>2</sub>O exchangeable); <sup>13</sup>CNMR (75 MHz, DMSO) δ ppm: 119.17 (1C, Ar), 120.55 (2C, pyridazine), 122.39 (1C, Ar), 122.61 (1C, Ar), 128.97 (1C, Ar), 129.37 (2C, Ar), 129.47 (1C, Ar), 131.22 (2C, Ar), 131.63 (1C, Ar), 140.36 (1C, Ar), 147.58 (1C, Ar), 156.54 (2C, pyridazine), 167.43 (1C, CO); EIMS (% rel. abundance): 374 (M<sup>+</sup>, 0.00), 161 (13.34), 137 (100), 120 (76.40), 92 (71.66). Anal. Calcd for C<sub>17</sub>H<sub>12</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>2</sub>: C, 54.42; H, 3.22; N, 14.93; Found C, 54.35; H, 3.45; N, 14.88.

*4-[[6-(2,6-Dichlorophenyl)amino]pyridazin-3-ylamino]benzoic acid (2f)*

Yield: 78 %; mp 144–145 °C; IR (cm<sup>-1</sup>): 3460–2549 (O–H and N–H), 1666 (C=O), 1624 (C=N); <sup>1</sup>HNMR (300 MHz, DMSO-*d*<sub>6</sub>) δ ppm: 6.57 (d, 1H, pyridazine), 6.60 (d, 1H, pyridazine), 7.62–7.65 (m, 3H, ArH), 7.82 (dd, 2H, Ar–H), 7.91 (dd, 2H, Ar–H), 8.02 (s, 1H, N–H D<sub>2</sub>O exchangeable), 9.94 (s, 1H, N–H D<sub>2</sub>O exchangeable); EIMS (% rel. abundance): 377 (M+2+H, 1.23), 161 (10.33), 144 (20.78), 137 (44.36), 92 (21.35). Anal. Calcd for C<sub>17</sub>H<sub>12</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>2</sub>: C, 54.42; H, 3.22; N, 14.93; Found C, 54.24; H, 3.63; N, 15.20.

*3-[[6-(2-Chloropyridin-3-yl)amino]pyridazin-3-ylamino]benzoic acid (2g)*

Yield: 64 %; mp 126–127 °C; IR (cm<sup>-1</sup>): 3425–2561 (O–H and N–H) 1685 (C=O), 1624 (C=N); <sup>1</sup>HNMR (300 MHz, DMSO-*d*<sub>6</sub>) δ ppm: 5.55 (s, 2H, N–H D<sub>2</sub>O exchangeable),

6.76 (d, 1H, pyridazine), 6.80 (d, 1H, pyridazine), 6.95–7.18 (m, 6H, ArH), 7.52 (s, 1H, ArH); EIMS (% rel. abundance): 341 ( $M^+$ , 0.00), 137 (100), 120 (49.68), 112 (5.44), 92 (66.97). Anal. Calcd for  $C_{16}H_{12}ClN_5O_2$ : C, 56.23; H, 3.54; N, 20.49; Found C, 56.44; H, 3.86; N, 20.65.

*4-[[6-(2-Chloropyridin-3-yl)amino]pyridazin-3-ylamino]benzoic acid (2h)*

Yield: 65 %; mp 139–140 °C; IR ( $cm^{-1}$ ): 3460–2549 (O–H and N–H), 1670 (C=O), 1615 (C=N);  $^1H$ NMR (300 MHz, DMSO- $d_6$ )  $\delta$  ppm: 5.86 (s, 2H, N–H  $D_2O$  exchangeable), 6.52 (d, 1H, pyridazine), 6.55 (d, 1H, pyridazine), 7.59–8.07 (m, 7H, ArH); EIMS (% rel. abundance): 341 ( $M^+$ , 0.05), 137 (89.47), 120 (100), 92 (48.93). Anal. Calcd for  $C_{16}H_{12}ClN_5O_2$ : C, 56.23; H, 3.54; N, 20.49; Found C, 56.12; H, 3.66; N, 20.45.

*3-[[6-(2-Carbamoylphenoxy)pyridazin-3-yl]amino]benzoic acid (4a)*

Yield: 68 %; mp 114–115 °C; IR ( $cm^{-1}$ ): 3394–2500 (O–H and N–H), 1678, 1660 (2C=O), 1631 (C=N);  $^1H$ NMR (300 MHz, DMSO- $d_6$ )  $\delta$  ppm: 5.30 (br s, 2H,  $NH_2$ ,  $D_2O$  exchangeable), 6.74 (d, 1H, pyridazine), 6.76 (d, 1H, pyridazine), 6.85–7.85 (m, 7H, ArH), 8.03 (s, 1H, ArH), 8.40 (s, 1H, N–H  $D_2O$  exchangeable), 13.02 (s, 1H, OH  $D_2O$  exchangeable); EIMS (% rel. abundance): 352 ( $M+2H$ , 22.48), 120 (100), 92 (82.91). Anal. Calcd for  $C_{18}H_{14}N_4O_4$ : C, 61.71; H, 4.03; N, 15.99; Found C, 61.45; H, 4.32; N, 16.18.

*4-[[6-(2-Carbamoylphenoxy)pyridazin-3-yl]amino]benzoic acid (4b)*

Yield: 70 %; mp 99–100 °C; IR ( $cm^{-1}$ ): 3437–2542 (O–H and N–H), 1680, 1666 (2C=O), 1624 (C=N);  $^1H$ NMR (300 MHz, DMSO- $d_6$ )  $\delta$  ppm: 5.70 (br s, 2H,  $NH_2$ ,  $D_2O$  exchangeable), 6.52 (d, 1H, pyridazine), 6.56 (d, 1H, pyridazine), 6.82–6.88 (m, 2H, ArH), 7.36–7.42 (m, 2H, ArH), 7.59–7.62 (m, 2H, ArH), 7.81–7.85 (m, 1H, ArH), 8.02 (d, 1H, ArH), 8.35 (s, 1H, N–H  $D_2O$  exchangeable), 12.97 (br s, 1H, OH  $D_2O$  exchangeable); EIMS (% rel. abundance): 350 ( $M^+$ , 14.71), 137 (76.05), 120 (100), 92 (50.70). Anal. Calcd for  $C_{18}H_{14}N_4O_4$ : C, 61.71; H, 4.03; N, 15.99; Found C, 61.55; H, 4.15; N, 15.78.

General procedure for 5a–c

An equimolar mixture of 3,6-dichloropyridazine and the appropriate substituted sulphamide (0.01 mol each) in isopropanol (30 mL) was heated under reflux for 4 h. The reaction mixture was concentrated under reduced pressure

to half its volume and cooled. The separated solid was filtered, washed with sodium carbonate solution (20 mL), dried then crystallized from isopropanol.

*N-Carbamimidoyl-4-[(6-chloropyridazin-3-yl)amino]benzenesulphonamide (5b)*

Yield: 65 %; mp 129–130 °C; IR ( $cm^{-1}$ ): 3498, 3441, 3394 (N–H and  $NH_2$ ), 1620 (C=N), 1384 and 1126 ( $SO_2$ );  $^1H$ NMR (300 MHz, DMSO- $d_6$ )  $\delta$  ppm: 5.60 (br s, 2H,  $NH_2$   $D_2O$  exchangeable), 6.51–6.54 (m, 3H, 2ArH and 1H pyridazine), 7.35–7.40 (m, 2H, ArH), 8.04 (d, 1H, pyridazine); EIMS (% rel. abundance): 324 ( $M-2$ , 0.06), 214 (96.43), 108 (100), 92 (75.20). Anal. Calcd for  $C_{11}H_{11}ClN_6O_2S$ : C, 40.43; H, 3.39; N, 25.72; Found C, 40.28; H, 3.13; N, 25.84.

*4-[(6-Chloropyridazin-3-yl)amino]-N-(pyrimidin-2-yl)benzenesulphonamide (5c)*

Yield: 55 %; mp 209–210 °C; IR ( $cm^{-1}$ ): 3468, 3375 (2N–H), 1627 (C=N), 1323 and 1153 ( $SO_2$ );  $^1H$ NMR (300 MHz, DMSO- $d_6$ )  $\delta$  ppm: 6.01 (s, 2H, 2NH  $D_2O$  exchangeable), 6.54 (d, 1H, pyridazine), 7.00 (t, 1H, pyrimidine), 6.78–6.81 (d, 2H, ArH), 7.58–7.72 (m, 2H, ArH), 8.05 (d, 1H, pyridazine), 8.46 (d, 2H, pyrimidine); EIMS (% rel. abundance): 364 ( $M+2$ , 0.05), 362 ( $M^+$ , 0.07), 185 (100), 108 (26.08), 92 (50.24). EIMS (% rel. abundance): Anal. Calcd for  $C_{14}H_{11}ClN_6O_2S$ : C, 46.35; H, 3.06; N, 23.16; Found C, 46.56; H, 2.89; N, 23.36.

*3-[[6-[(4-Sulphamoylphenyl)amino]pyridazin-3-yl]amino]benzoic acid (6a)*

Yield: 70 %; mp 119–120 °C; IR ( $cm^{-1}$ ): 3460, 3375, 3340, 3244 (N–H and  $NH_2$ ), 1678 (C=O), 1627 (C=N), 1388 and 1145 ( $SO_2$ );  $^1H$ NMR (300 MHz, DMSO- $d_6$ )  $\delta$  ppm: 5.30 (s, 1H, NH  $D_2O$  exchangeable), 5.80 (s, 2H,  $NH_2$   $D_2O$  exchangeable), 6.56 (d, 1H, pyridazine), 6.59 (d, 1H, pyridazine), 6.73–6.77 (m, 1H, ArH), 6.89 (s, 1H, NH  $D_2O$  exchangeable), 7.05–7.17 (m, 5H, ArH), 7.45 (d, 2H, ArH); EIMS (% rel. abundance): 385 ( $M^+$ , 0.00), 172 (100), 156 (84.02), 108 (67.31), 92 (85.17), 80 (23.64). Anal. Calcd for  $C_{17}H_{15}N_5O_4S$ : C, 52.98; H, 3.92; N, 18.17; Found C, 53.05; H, 3.88; N, 18.23.

*4-[[6-[(4-Sulphamoylphenyl)amino]pyridazin-3-yl]amino]benzoic acid (6b)*

Yield: 72 %; mp 144–145 °C; IR ( $cm^{-1}$ ): 3475, 3375, 3267, 3217 (N–H and  $NH_2$ ), 1680 (C=O), 1627 (C=N), 1315 and 1145 ( $SO_2$ );  $^1H$ NMR (300 MHz, DMSO- $d_6$ )  $\delta$  ppm: 5.40 (s, 1H, NH  $D_2O$  exchangeable), 5.80 (s, 2H,  $NH_2$   $D_2O$  exchangeable), 6.56–6.78 (m, 6H, 4 ArH and 2H

pyridazine), 6.89 (s, 1H, NH D<sub>2</sub>O exchangeable), 7.43–7.63 (m, 4H, ArH); <sup>13</sup>CNMR (75 MHz, DMSO) δ ppm: 112.31 (2C, Ar), 112.44 (2C, Ar), 116.68 (2C, Ar), 127.32 (2C, pyridazine), 129.82 (2C, Ar), 131.14 (2C, Ar), 151.80 (2C, Ar), 153.03 (2C, pyridazine), 167.43 (1C, CO); EIMS (% rel. abundance): 384 (M<sup>+</sup>–1, 0.04), 172 (100), 156 (78.20), 108 (58.57), 92 (74.43), 80 (17.80). Anal. Calcd for C<sub>17</sub>H<sub>15</sub>N<sub>3</sub>O<sub>4</sub>S: C, 52.98; H, 3.92; N, 18.17; Found C, 53.15; H, 3.74; N, 18.35.

3-[[6-[(4-(*N*-Carbamimidoylsulphamoyl)phenyl)-amino]pyridazin-3-yl]amino] benzoic acid (**6c**)


Yield: 68 %; mp 139–140 °C; IR (cm<sup>-1</sup>): 3433–2600 (N–H and O–H), 1654 (C=O), 1631 (C=N), 1307 and 1185 (SO<sub>2</sub>); <sup>1</sup>HNMR (300 MHz, DMSO-*d*<sub>6</sub>) δ ppm: 4.12 (br s, 2H, NH<sub>2</sub>

D<sub>2</sub>O exchangeable), 6.58 (d, 1H, pyridazine), 6.62 (d, 1H, pyridazine), 6.66 (s, 2H, 2NH D<sub>2</sub>O exchangeable), 7.23–8.04 (m, 8H, ArH); EIMS (% rel. abundance): 429 (M+2H, 3.55), 137 (57.17), 92 (45.72), 79 (9.60). Anal. Calcd for C<sub>18</sub>H<sub>17</sub>N<sub>7</sub>O<sub>4</sub>S: C, 50.58; H, 4.01; N, 22.94; Found C, 50.33; H, 4.34; N, 22.70.

4-[[6-[(4-(*N*-Carbamimidoylsulphamoyl)phenyl)-amino]pyridazin-3-yl]amino] benzoic acid (**6d**)

Yield: 72 %; mp 124–125 °C; IR (cm<sup>-1</sup>): 3448–2700 (N–H and O–H), 1650 (C=O), 1627 (C=N), 1327 and 1138 (SO<sub>2</sub>); <sup>1</sup>HNMR (300 MHz, DMSO-*d*<sub>6</sub>) δ ppm: 5.80 (br s, 2H, NH<sub>2</sub> D<sub>2</sub>O exchangeable), 6.51–6.55 (m, 6H, 4 ArH and 2H pyridazine), 6.70 (s, 2H, 2NH D<sub>2</sub>O exchangeable), 7.36 (d, 2H, ArH), 7.58 (d, 2H, ArH); EIMS (% rel. abundance):

**Table 1** Cytotoxicity of the tested compounds against HT-29 colon cell line in vitro



Compound No.	X	R	R <sup>1</sup>	R <sup>2</sup>	HT-29 (IC <sub>50</sub> ) <sup>a,b</sup> μM
<b>2a</b>	NH	H	COOH	4-Cl	15.3
<b>2b</b>	NH	COOH	H	4-Cl	3.9
<b>2c</b>	NH	H	COOH	2,4-Cl <sub>2</sub>	31.4
<b>2d</b>	NH	COOH	H	2,4-Cl <sub>2</sub>	NA <sup>c</sup>
<b>2e</b>	NH	H	COOH	2,6-Cl <sub>2</sub>	103.8
<b>2f</b>	NH	COOH	H	2,6-Cl <sub>2</sub>	119.5
<b>2g</b>	–	H	COOH	–	87.0
<b>2h</b>	–	COOH	H	–	69.2
<b>4a</b>	O	H	COOH	2-CONH <sub>2</sub>	126.4
<b>4b</b>	O	COOH	H	2-CONH <sub>2</sub>	50.53
<b>6a</b>	–	H	COOH	H	NA <sup>c</sup>
<b>6b</b>	–	COOH	H	H	198.1
<b>6c</b>	–	H	COOH	C(NH)NH <sub>2</sub>	104.4
<b>6d</b>	–	COOH	H	C(NH)NH <sub>2</sub>	NA <sup>c</sup>
<b>6e</b>	–	H	COOH		NA <sup>c</sup>
<b>6f</b>	–	COOH	H		NA <sup>c</sup>
<b>Vatalanib<sup>d</sup></b>					22.11

<sup>a</sup> IC<sub>50</sub>: dose of the compound which inhibit tumor cell proliferation by 50 %

<sup>b</sup> Values are means of three experiments

<sup>c</sup> NA: compounds having IC<sub>50</sub> value > 200 μM

<sup>d</sup> Used as positive control

428 (M+H, 0.01), 92 (0.25), 108 (0.37), 80 (100). Anal. Calcd for C<sub>18</sub>H<sub>17</sub>N<sub>7</sub>O<sub>4</sub>S: C, 50.58; H, 4.01; N, 22.94; Found C, 50.25; H, 4.14; N, 23.18.

*3-[[6-[(4-(N-(Pyrimidin-2-yl)sulphamoyl)phenyl)amino]pyridazin-3-yl]amino] benzoic acid (6e)*

Yield: 65 %; mp 237–238 °C; IR (cm<sup>-1</sup>): 3425–2519 (N–H and O–H), 1651 (C=O), 1600 (C=N), 1323 and 1157 (SO<sub>2</sub>); <sup>1</sup>HNMR (300 MHz, DMSO-*d*<sub>6</sub>) δ ppm: 6.01 (br s, 3H, 3NH D<sub>2</sub>O exchangeable), 6.53–6.56 (m, 6H, 4ArH and 2H pyridazine), 7.00 (t, 1H, pyrimidine), 7.58–7.61 (m, 4H, ArH), 8.46 (d, 2H, pyrimidine); EIMS (% rel. abundance): 463 (M<sup>+</sup>, 11.52), 385 (12.83), 326 (12.07), 136 (13.48), 95 (100), 80 (86.63). Anal. Calcd for C<sub>21</sub>H<sub>17</sub>N<sub>7</sub>O<sub>4</sub>S: C, 54.42; H, 3.70; N, 21.15; Found C, 54.13; H, 3.66; N, 21.22.

*4-[[6-[(4-(N-(Pyrimidin-2-yl)sulphamoyl)phenyl)amino]pyridazin-3-yl]amino] benzoic acid (6f)*

Yield: 74 %; mp 221–222 °C; IR (cm<sup>-1</sup>): 3425–2661 (N–H and O–H), 1651 (C=O), 1615 (C=N), 1323 and 1157 (SO<sub>2</sub>); <sup>1</sup>HNMR (300 MHz, DMSO-*d*<sub>6</sub>) δ ppm: 6.01 (br s, 3H, 3NH D<sub>2</sub>O exchangeable), 6.53–6.58 (m, 6H, 4ArH and 2H pyridazine), 7.00 (t, 1H, pyrimidine), 7.57–7.62 (m, 4H,


ArH), 8.45 (d, 2H, pyrimidine); EIMS (% rel. abundance): 462 (M–1, 6.07), 419 (7.31), 136 (13.48), 95 (94.28), 81 (12.74). Anal. Calcd for C<sub>21</sub>H<sub>17</sub>N<sub>7</sub>O<sub>4</sub>S: C, 54.42; H, 3.70; N, 21.15; Found C, 54.72; H, 3.55; N, 21.05.

Biological studies



*In vitro cytotoxicity assay*

The cytotoxic activity was measured in vitro using the sulphorhodamine B (SRB) colorimetric assay using the method of Skehan et al. (1990). Cells were inoculated in 96-well microtiter plate (104 cells/well) for 24 h before treatment with the compound(s) to allow attachment of cell to the wall of the plate. Test compounds were dissolved in DMSO and diluted with saline to the appropriate volume. Different concentrations of the compound under test (0.1, 2.5, 5, and 10 mmol/mL) were added to the cell monolayer. Triplicate wells were prepared for each individual dose. Monolayer cells were incubated with the compound(s) for 48 h at 37 °C and in atmosphere of 5 % CO<sub>2</sub>. After 48 h, cells were fixed, washed, and stained for 30 min with 0.4 % (w/v) SRB dissolved in 1 % acetic acid. Unbound dye was removed by four washes with 1 % acetic acid, and attached stain was recovered with Tris–EDTA buffer.

**Scheme 1** Reagents and conditions: **a** K<sub>2</sub>CO<sub>3</sub>, isopropanol, 4 h, **b** 3- or 4-aminobenzoic acid, isopropanol, 4–5 h



**Scheme 2** Reagents and conditions: **a**  $K_2CO_3$ , isopropanol, 4 h, **b** 3- or 4-aminobenzoic acid, isopropanol, 4–5 h



**Fig. 2** **a** Docked pose of **2a** in VEGFR-2 binding site generated by MOE docking. **b** Simplified 2D ligand interaction of **2a**. The most important amino acids are shown together with their respective numbers. Compound **2a** forms a hydrogen bond with Glu883 through its anilino nitrogen, and other hydrogen bond with Lys866 through the carboxylate oxygen

Colour intensity was measured in an ELISA reader. The relation between surviving fraction and drug concentration is plotted to get the survival curve for tumor cell line after the specified time. The concentration required for 50 % inhibition of cell viability ( $IC_{50}$ ) was calculated (Table 1).

## Results and discussion

The synthetic route for target compounds **2a–h** and **4a, b** is outlined in Scheme 1. The intermediates **1a–h** and **3** were prepared from the commercially available 3,6-dichloropyridazine and different primary amino compounds or salicylamide as a starting materials, according to the reported procedure (Abouzid et al. 2012). The target anilino substituted pyridazine benzoic acids **2a–h** and the corresponding 2-aminocarbonylphenoxy analogues **4a, b** were obtained in 60–78 % yields by heating the precursors **1a–h** or **3** with either 3-aminobenzoic acid or 4-aminobenzoic acid in refluxing isopropanol for 4–5 h. The newly synthesised compounds were characterized by IR,  $^1H$ NMR,  $^{13}C$ NMR and mass spectral data as well as elemental analyses.

Support for the structure of the compounds **2a–h** was evidenced by the presence of prominent bands in the IR spectra for the carboxylic acid C=O str. ( $1,678–1,666\text{ cm}^{-1}$ ). The structures were further established by  $^1H$ NMR spectral data. In the compounds **2a–f**, signals due to the two NH (controlled with  $D_2O$ ) were resonated at (8.02–8.04) and (8.81–9.95) ppm, while the signals due to OH group did not appear. In the carboxamide derivatives **4a, b**, IR spectra showed two bands for the carboxylic acid and the amide C=O str. In their  $^1H$ NMR spectra, the broad  $NH_2$  signals (controlled with  $D_2O$ ) were observed at 5.20–5.80 ppm.

In Scheme 2, using methodology previously described (Abouzid et al. 2012), the intermediates **5a–c** were synthesized from a commercially available 3,6-dichloropyridazine and either sulphanilamide, sulphadiazine or sulphadimidine. Thereafter, reaction of **5a–c** with either 3-aminobenzoic acid or 4-aminobenzoic acid afforded **6a–f** in 65–74 % yields.

The two new intermediates **5b, c** and the final targets **6a–f** displayed IR,  $^1H$ NMR,  $^{13}C$ NMR, mass spectral data and elemental analyses consistent with the assigned structures.



results as well as to help us in understanding the various interactions between the ligands and enzyme active site.

The X-ray crystallographic structure of VEGFR-2 complexed with vatalanib was utilized in our docking studies (PDB ID: 1YWN). All water molecules in the experimental structure were removed and hydrogen atoms were added and the protonation states of the amino acid residues were assigned using the Protonate3D algorithm. Ligand molecules were modelled using MOE builder, and the structures were energy minimized using the MMFF94x force field. Validation of the function implemented in MOE was done by docking of the native ligand into its binding site. The docked results were compared to the crystal structure of the bound ligand–protein complex.

Next, we performed docking studies to our synthesized compounds, and the final docked complexes of ligand–enzyme were selected according to the criteria of interaction energy combined with geometrical matching quality.

In summary, the biological results revealed that, small lipophilic electron withdrawing substituents on the benzene ring enhances the cytotoxic effect. This was evident from the appreciable activity observed by the 4-chloro derivatives **2a** and **2b**. This result may be substantiated on the basis of various reported SAR studies (Virasodia et al. 2009; Zhang et al. 2010), which demonstrates the importance of chloro substituent in the position 3 or 4 of the benzene ring.

On the other hand, introduction of a second substituent to the benzene ring results in decline of activity, as shown by 2,4- and 2,6-dichloro derivatives, **2c**, **2d**, **2e** and **2f**. Besides, the presence of bulky sulphonamido substituent abolishes the activity, suggesting a relatively restricted binding area.

These preliminary encouraging results of biological screening of some of the tested compounds could offer an excellent framework in this field, that may lead to discover novel leads for future drug development.

Docking studies revealed that the compounds **2a** and **2b** showed similar binding mode to vatalanib with binding energy scores equal to  $-11.0079$ ,  $-11.8305$  and  $-14.2118$  respectively, which may explain their potential anticancer activity (Figs. 2, 3, 4).

**Acknowledgments** The authors thank staff members of the Pharmacology Department, Faculty of Pharmacy, Ain Shams University for carrying out the biological screening.

## References

Abd El-Ghaffar, N.F., Mohamed, M.K., Kadah, M.S., Radwan, A.M., Said, G.H., and Abd el Al, S.N. 2011. Synthesis and anti-tumor activities of some new pyridazinones containing the 2-phenyl-1*H*-indolyl moiety. *Journal of Chemical and Pharmaceutical Research* 3: 248–259.

Abouzid, K.A.M., N.A. Khalil, E.M. Ahmed, A. Esmat, and A.M. Al-Abd. 2012. Design, synthesis, and evaluation of anti-inflammatory and ulcerogenicity of novel pyridazinone derivative. *Medicinal Chemistry Research* 21: 3581–3590.

Ahmad, S., I.G. Rathish, S. Bano, M.S. Alam, and K.K. Javed. 2010. Synthesis and biological evaluation of some novel 6-aryl-2-(*p*-sulfamylphenyl)-4,5-dihydropyridazin-3(2*H*)-ones as anti-cancer, antimicrobial, and anti-inflammatory agents. *Journal of Enzyme Inhibition and Medicinal Chemistry* 25: 266–271.

Ahman, T., and T. Eisen. 2004. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. *Clinical Cancer Research* 10: 6388–6392.

Coelho, A., E. Sotelo, and E. Ravina. 2003. Pyridazine derivatives. Part 33. Sonogashira approaches in the synthesis of 5-substituted-6-phenyl-3(2*H*)pyridazinones. *Tetrahedron* 59: 2477–2484.

Dvorak, H.F. 2002. Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. *Journal of Clinical Oncology* 20: 4368–4380.

Eckhardt, S. 2002. Recent progress in the development of anticancer agents. *Current Medicinal Chemistry: Anti-Cancer Agents* 2: 419–439.

Harris, R.R., L. Black, S. Surapaneni, T. Kolasa, S. Majest, M.T. Namovic, G. Grayson, V. Komater, D. Wilcox, L. King, K. Marsh, M.F. Jarvis, M. Nuss, H. Nellans, L. Pruesser, G.A. Reinhardt, B. Cox, P. Jacobson, A. Stewart, M. Coghlan, G. Carter, and R.L. Bell. 2004. ABT-963 [2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonylphenyl)-2*H*-pyridazin-3-one], a highly potent and selective disubstituted pyridazinone cyclooxygenase-2 inhibitor. *Journal of Pharmacology and Experimental Therapeutics* 311: 904–912.

Kamal, A., D. Dastagiri, M.J. Ramaiah, J.S. Reddy, E.V. Bharathi, M.K. Reddy, M.V. Sagar, T.L. Reddy, S.N. Pushpavalli, and M. Pal-Bhadra. 2011. Synthesis and apoptosis inducing ability of new anilino substituted pyrimidine sulfonamides as potential anticancer agents. *European Journal of Medicinal Chemistry* 46: 5817–5824.

Kandile, N.G., M.I. Mohamed, H. Zaky, and H.M. Mohamed. 2009. Novel pyridazine derivatives: Synthesis and antimicrobial activity evaluation. *European Journal of Medicinal Chemistry* 44: 1989–1996.

Kwon, S.K., and A. Moon. 2005. Synthesis of 3-alkylthio-6-allylthiopyridazine derivatives and their antihepatocarcinoma activity. *Archives of Pharmacol Research* 28: 391–394.

Lee, C.W., D.H. Hong, S.B. Han, S.H. Jong, H.C. Kim, R.L. Fine, S.H. Lee, and H.M. Kim. 2002. A novel stereo-selective sulfonylurea, 1-[1-(4-aminobenzoyl)-2,3-dihydro-1*H*-indol-6-sulfonyl]-4-phenyl-imidazolidin-2-one, has antitumor efficacy in in vitro and in vivo tumor models. *Biochemical Pharmacology* 64: 473–480.

Livermore, D.G.H., R.C. Bethell, and N. Cammack. 1993. Synthesis and anti-HIV-1 activity of a series of imidazo[1,5-*b*]pyridazines. *Journal of Medicinal Chemistry* 36: 3784–3794.

Mariño, E.L., A. Dominguez-Gil, J.M. Taberero, and J.G. Macias. 1980. Influence of hepatic and renal disorders on the pharmacokinetics of sulfachloropyridazine. *International Journal of Clinical Pharmacology Therapy and Toxicology* 18: 10–14.

Morabito, A., E. De Maio, M. Di Maio, N. Normanno, and F. Perrone. 2006. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: Current status and future directions. *Oncologist* 11: 753–764.

Piatnitski, E.L., M.A. Duncton, A.S. Kiselyov, R. Katoch-Rouse, D. Sherman, D.L. Milligan, C. Balagtas, W.C. Wong, J. Kawakami, and J.F. Doody. 2005. Arylphthalazines: Identification of a new phthalazine chemotype as inhibitors of VEGFR kinase. *Bioorganic & Medicinal Chemistry Letters* 15: 4696–4698.

Podar, K., L.P. Catley, Y. Tai, R. Shringarpure, P. Carvalho, T. Hayashi, R. Burger, R.L. Schlossman, P.G. Richardson, L.N. Pandite, R. Kumar, T. Hideshima, D. Chauhan, and K.C. Anderson. 2004. GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. *Blood* 103: 3474–3479.

- Rathish, I.G., K. Javed, S. Ahmad, S. Bano, M.S. Alam, M. Akhter, K.K. Pillai, S. Ovais, and M. Samim. 2012. Synthesis and evaluation of anticancer activity of some novel 6-aryl-2-(p-sulfamylphenyl)-pyridazin-3(2H)-ones. *European Journal of Medicinal Chemistry* 49: 304–309.
- Rojo, F., J. Albanell, A. Rovira, J.M. Corominas, and F. Manzarbeitia. 2008. Targeted therapies in breast cancer. *Seminars in Diagnostic Pathology* 25: 245–261.
- Rubat, C., P. Coudert, B. Refouvelet, P. Tronche, and P. Bastide. 1990. Anticonvulsant activity of 3-oxo-5-substituted benzylidene-6-methyl-(4H)-2-pyridazinyl acetamides and 2-pyridazinylacetylhydrazides. *Chemical & Pharmaceutical Bulletin* 38: 3009–3013.
- Scott, E.N., G. Meinhardt, C. Jacques, D. Laurent, and A.L. Thomas. 2007. Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours. *Expert Opinion on Investigational Drugs* 16: 367–379.
- Siddiqui, A.A., R. Mishra, and M. Shaharyar. 2010. Synthesis, characterization and antihypertensive activity of pyridazinone derivatives. *European Journal of Medicinal Chemistry* 45: 2283–2290.
- Sircar, I., R.E. Weishaar, D. Kobylarz, W.H. Moos, and J.A. Bristol. 1987. Cardiotoxic agents. 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure–activity relationships and correlation with in vivo positive inotropic activity. *Journal of Medicinal Chemistry* 30: 1955–1962.
- Skehan, P., R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J.T. Warren, H. Bokesch, S. Kenney, and M.R. Boyd. 1990. New colorimetric cytotoxicity assay for anticancer-drug screening. *Journal of the National Cancer Institute* 82: 1107–1112.
- Virasodia, V., A. Manvar, K. Upadhyay, R. Loria, D. Karia, M. Jaggi, A. Singh, R. Mukherjee, M.S. Shaikh, E.C. Coutinho, and A. Shah. 2009. Synthesis of 1-(2,6-dichlorophenyl)-3-methylene-1,3-dihydro-indol-2-one derivatives and in vitro anticancer evaluation against SW620 colon cancer cell line. *European Journal of Medicinal Chemistry* 44: 1355–1362.
- Zhang, S., Y. Zhao, Y. Liu, D. Chen, W. Lan, Q. Zhao, C. Dong, L. Xia, and P. Gong. 2010. Synthesis and antitumor activities of novel 1,4-disubstituted phthalazine derivatives. *European Journal of Medicinal Chemistry* 45: 3504–3510.